NASDAQ:EOLS - Evolus Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $26.17 -0.84 (-3.11 %) (As of 07/15/2018 04:00 PM ET)Previous Close$26.17Today's Range$25.30 - $26.879752-Week Range$6.75 - $39.50Volume212,373 shsAverage Volume294,335 shsMarket Capitalization$618.66 millionP/E Ratio-96.93Dividend YieldN/ABetaN/A Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California. Receive EOLS News and Ratings via Email Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:EOLS CUSIPN/A Webwww.evolus.com Phone949-284-4555 Debt Debt-to-Equity RatioN/A Current Ratio13.84 Quick Ratio13.84 Price-To-Earnings Trailing P/E Ratio-96.93 Forward P/E Ratio-15.86 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees21 Outstanding Shares23,640,000Market Cap$618.66 Evolus (NASDAQ:EOLS) Frequently Asked Questions What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." How were Evolus' earnings last quarter? Evolus Inc (NASDAQ:EOLS) issued its earnings results on Thursday, May, 10th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.06. View Evolus' Earnings History. What price target have analysts set for EOLS? 4 brokerages have issued 1 year price targets for Evolus' stock. Their predictions range from $24.00 to $35.00. On average, they anticipate Evolus' stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price. View Analyst Ratings for Evolus. What is the consensus analysts' recommendation for Evolus? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Evolus stock? Here are some recent quotes from research analysts about Evolus stock: 1. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for EOLS shares to $35 from $25. The increase in our PT is driven by multiple expansion now that visibility has improved for the peak sales potential of DWP-450 (new CEO from AGN (Neutral), new CFO from RVNC (OW), expansion of commercial team and completion of response to CRL this summer). We use a blend of DCF and EV/ EBITDA analysis to arrive at our new $35 PT." (6/7/2018) 2. Mizuho analysts commented, "We lowered our estimates and pushed out the forecast (U.S. launch in 3Q:19 vs. 1Q:19 previously), driving a PT reduction to $16 from $21. Reiterate Buy." (5/16/2018) 3. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (5/15/2018) Are investors shorting Evolus? Evolus saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 1,724,506 shares, an increase of 68.8% from the May 15th total of 1,021,392 shares. Based on an average daily volume of 904,889 shares, the days-to-cover ratio is currently 1.9 days. Currently, 35.2% of the company's stock are short sold. View Evolus' Current Options Chain. Who are some of Evolus' key competitors? Some companies that are related to Evolus include TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH), Phibro Animal Health (PAHC) and Insmed (INSM). Who are Evolus' key executives? Evolus' management team includes the folowing people: Dr. Rui Avelar M.D., Chief Medical Officer (Age 56)Mr. David Moatazedi, Pres & CEO (Age 40)Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 59)Dr. J. Christopher Marmo Ph.D., Chief Operating Officer (Age 49)Jeffrey J. Plumer, VP of Legal When did Evolus IPO? (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. When does Evolus' lock-up period expire? Evolus' lock-up period expires on Tuesday, August 7th. Evolus had issued 5,000,000 shares in its public offering on February 8th. The total size of the offering was $60,000,000 based on an initial share price of $12.00. After the end of Evolus' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Has Evolus been receiving favorable news coverage? Media headlines about EOLS stock have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evolus earned a coverage optimism score of 0.07 on Accern's scale. They also gave news articles about the company an impact score of 47.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. How do I buy shares of Evolus? Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $26.17. How big of a company is Evolus? Evolus has a market capitalization of $618.66 million. The company earns $-4,480,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Evolus employs 21 workers across the globe. How can I contact Evolus? Evolus' mailing address is 17901 Von Karman Avenue Suite 150, Irvine CA, 92614. The company can be reached via phone at 949-284-4555 or via email at [email protected] MarketBeat Community Rating for Evolus (NASDAQ EOLS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 62 (Vote Outperform)Underperform Votes: 52 (Vote Underperform)Total Votes: 114MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?